

Supplemental Material to:

**Raffaella Barbano, Lucia Anna Muscarella, Barbara Pasculli,
Vanna Maria Valori, Andrea Fontana, Michelina Coco,
Annamaria la Torre, Teresa Balsamo, Maria Luana Poeta,
Giovanni Francesco Marangi, Evaristo Maiello, Marina
Castelvetere, Fabio Pellegrini, Roberto Murgio, Vito
Michele Fazio and Paola Parrella**

**Aberrant keap1 methylation in breast cancer and
association with clinicopathological features**

Epigenetics 2012; 8(1)

<http://dx.doi.org/10.4161/epi.23319>


<http://www.landesbioscience.com/journals/epigenetics/article/23319>

Supplemental Table 1. Descriptive statistics of study population (n=102).

Characteristics	n	%
Family History (no <i>BRCA1/BRCA2</i> related)		
No	90	88.2
Yes	12	11.8
Menopause		
No	31	30.4
Yes	71	69.6
Tumor histotype		
Ductal	90	88.3
Lobular	8	7.8
Others	4	3.9
Tumor		
T1c	38	37.2
T2	42	41.2
T3	3	2.9
T4	15	14.8
Missing	4	3.9
Lymph nodes		
N0	41	40.2
N1	31	30.4
N2	16	15.7
N3	14	13.7
Metastases		
0	96	94.1
1	6	5.9
Stage		
I	23	22.6
II	41	40.2
III	28	27.4
IV	6	5.9
Missing	4	3.9
Er status		
Positive	68	66.7
Negative	34	33.3
PgR status		
Positive	62	60.8
Negative	40	39.2
<i>HER2</i> amplification/overexpression		
Negative	62	60.8
Positive	25	24.5
Missing	15	14.7
Receptor Classification		
Er positive Her2 negative	42	41.2
Er positive Her2 positive	11	10.8
Triple Negative	20	19.6
<i>HER2</i> amplified only	14	13.7
Not classified	15	14.7
Grade		
G1	10	9.8
G2	37	36.3
G3	39	38.2
missing	16	15.7
Ki67/Mib1 labelling index		
≤30%	46	45.0
>30	40	39.2
Missing	16	15.8
Adjuvant Treatment (n=96)		
Hormone therapy alone	17	17.7
Hormone therapy + Chemotherapy	45	46.9
Chemotherapy	34	35.4
Adjuvant Chemotherapy regimen* (n=79)		
FEC	32	40.5
EC/D	30	38.0
CMF	11	13.9
EPI/VNR	6	7.6

Data are reported as median along with interquartile range (IQR) for continuous variables and as frequencies and percentages for categorical variables.

*FEC, 6 cycles of combination therapy with Fluorouracil (5FU), epirubicin and cyclophosphamide; EC/D, 4 cycles of combination therapy with epirubicin and cyclophosphamide followed by 4 cycles of docetaxel.



Cut-off that minimizes the distance between the curve and upper left corner.